ArticleCureus2026
Posttraumatic Stress Disorder (PTSD) NAD/Sirtuin Deficiency and SARM1-Mediated Synaptic Vulnerability: Evidence for Accelerated Brain Aging Subtypes.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anxiety disorders and posttraumatic stress disorder (PTSD) often occur alongside signs of accelerated biological aging, yet the molecular pathways that connect genetic liability to synaptic and circuit-level dysfunction remain unclear. We performed a multi-gene-set transcriptome-wide association study using large-scale genome-wide association study (GWAS) summary statistics for anxiety disorders and PTSD, with a focus on curated aging-related pathways across brain regions involved in fear, reward, memory, and stress regulation. The analysis identified 185 significant enrichments, with strong cross-disorder concordance in senescence, telomere maintenance, and mitochondrial modules. PTSD showed a distinctive negative signature in nicotinamide adenine dinucleotide (NAD) metabolism and sirtuin-related pathways, most prominently driven by sirtuin 3 (SIRT3), together with evidence of sterile alpha and Toll/interleukin-1 receptor motif-containing 1 (SARM1)-linked axonal and synaptic vulnerability. Anxiety disorders showed stronger enrichment in mitochondrial intrinsic apoptosis and inflammatory-redox signaling, alongside glutamatergic and astrocytic plasticity changes. Both conditions shared senescence and deoxyribonucleic acid (DNA)-damage programs, with NIMA-related kinase 4 (NEK4) emerging as a common driver. These pathways converged on complement-mediated pruning and presynaptic remodeling, suggesting a mechanistic bridge from cellular aging to fear and reward circuit dysfunction. Together, the findings support an association-based model in which genetic liability for anxiety disorders and PTSD converges on stress-aging biology at the synapse, while diverging by disorder. This framework points to candidate biologically distinct subtypes and offers practical opportunities for biomarker development, patient stratification, and subtype-guided therapeutic strategies. These subtype labels are proposed biological hypotheses rather than validated clinical categories.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.